Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 280

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 280
---
 preferred shares are classified outside of shareholders’ deficit as a result of
these in-substance contingent redemption rights.

As of December 31, 2024, the Company
did not adjust the carrying values of the preferred shares to the deemed liquidation values of such shares since a liquidation event
was not probable of occurring.

<div align='center'>F-26</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 11:- | SHAREHOLDERS’ DEFICIT |

:

Ordinary Shares confer to holders
the right to receive notice to participate and vote in the general meetings of the Company and the right to receive dividends if declared.
However, certain ordinary shareholders, who received those shares upon their exercise of options pursuant to the Company’s share
option plan, have signed an irrevocable proxy appointing the Chairman of the Company’s board of directors to use the voting rights
of their Ordinary Shares.

:

As of December 31, 2024 and 2023,
there 79,290 options outstanding to purchase its Ordinary Shares, at an exercise price of $3.97; of which 41,790 options were held by
Company’s service providers and 37,500 options were held by a director of the Company. The outstanding share options were granted
in prior years and are fully vested and exercisable as of January 1, 2023. Such share options will expire in December 2029.

During the years ended December 31,
2024 and 2023, the Company didn’t grant any share options.

| NOTE 12:- | SELECTED STATEMENTS OF COMPREHENSIVE INCOME DATA |

| a. | Research and development expenses: |

|                               |     | Year Ended December 31, |   2024 |   |     |   | 2023 |
|:------------------------------|:----|:------------------------|-------:|:--|:----|:--|-----:|
| Subcontractors                |     | $                       |    209 |   |     | $ |  675 |
| Materials                     |     |                         |      - |   |     |   |   54 |
| Patents                       |     |                         |      - |   |     |   |   39 |
| Salaries and related expenses |     |                         |      3 |   |     |